European Cancer Congress 2013: Abstract Submission

In 2011, the Congress Secretariat had the largest number of abstracts ever submitted. The ECC 2013 promises to be an even stronger pioneering programme for showcasing the latest developments in practice-changing studies

Abstract submission deadlines

Regular Abstract Submission

Present your work at the largest platform for practice-changing data in Europe. Regular abstract submission for the 17th ECCO, 38th ESMO, 32nd ESTRO European Cancer Congress is open from 25 January to 17 April 2013 only.

Take the opportunity to become part of the pioneering 2013 programme for this meeting from 27 September to 1 October by submitting an abstract. 

By submitting an abstract, you underpin the importance of medical oncology and ensure that you make a tangible contribution in establishing standards in Europe for the field of oncology now and into the future.  Presenting your data at the congress will also help you reach beyond the professional community, creating global outreach for your messages to lay audiences also, through the more than 350 members of the media expected to attend the event. In 2011, the largest number of participants attended, the biggest number of abstracts ever was submitted, and the highest amount of new data was presented.

Late-Breaking Abstract Submission

A call for Late-Breaking Abstracts will be made in July 2013. Online submission will be open on from 24 July - 7 August 2013.

Late-breaking abstracts describe the latest advances that will change our daily clinical practice and have not been previously submitted. They should highlight novel and practice-changing studies. The late-breaking abstract deadline is not an extension of the general submission deadline. Focus is placed on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts:

• Practice-changing prospective Phase III clinical trial
• A Phase II study showing anti-tumour activity in a novel context
• An early clinical trial with novel proof-of-principle data
• Demonstration of novel cancer biology with therapeutic implications

In each case the results should not have been fully available by the general abstract submission deadline. The data in the abstract cannot be published (manuscript or abstract) prior to the Congress.

For more information about abstract submission, please contact Davi Kaur .